Pyxis Oncology annual stock-based compensation
2020
2021
2022
2023
2024
2025
Pyxis Oncology Stock-Based Compensation Growth & History (PYXS)
Pyxis Oncology's stock-based compensation was $11.8M for fiscal 2025.
View full Pyxis Oncology company overviewPyxis Oncology annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.8M | −$1.1M | −8.84% |
| 2024 | 2024-12-31 | $12.9M | −$4.0M | −23.61% |
| 2023 | 2023-12-31 | $16.9M | $1.2M | +7.50% |
| 2022 | 2022-12-31 | $15.8M | $9.3M | +144.74% |
| 2021 | 2021-12-31 | $6.4M | $6.4M | +14538.64% |
| 2020 | 2020-12-31 | $44,000 | — | — |
Pyxis Oncology quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.5M | $2.5M | +83.35% |
| Q1 2026 | 2026-03-31 | $1.2M | −$2.4M | −66.68% |
| Q4 2025 | 2025-12-31 | $2.1M | −$691,000 | −24.92% |
| Q3 2025 | 2025-09-30 | $3.1M | $92,000 | +3.09% |
| Q2 2025 | 2025-06-30 | $3.0M | $144,000 | +5.02% |
| Q1 2025 | 2025-03-31 | $3.6M | −$689,000 | −15.95% |
| Q4 2024 | 2024-12-31 | $2.8M | −$442,000 | −13.75% |
| Q3 2024 | 2024-09-30 | $3.0M | −$2.2M | −42.44% |
| Q2 2024 | 2024-06-30 | $2.9M | −$797,000 | −21.73% |
| Q1 2024 | 2024-03-31 | $4.3M | −$564,000 | −11.55% |
| Q4 2023 | 2023-12-31 | $3.2M | −$683,000 | −17.52% |
| Q3 2023 | 2023-09-30 | $5.2M | $730,000 | +16.41% |
| Q2 2023 | 2023-06-30 | $3.7M | −$345,000 | −8.60% |
| Q1 2023 | 2023-03-31 | $4.9M | $1.5M | +43.48% |
| Q4 2022 | 2022-12-31 | $3.9M | $786,000 | +25.26% |
| Q3 2022 | 2022-09-30 | $4.4M | $4.1M | +1349.19% |
| Q2 2022 | 2022-06-30 | $4.0M | $3.4M | +601.57% |
| Q1 2022 | 2022-03-31 | $3.4M | $954,000 | +38.94% |
| Q4 2021 | 2021-12-31 | $3.1M | — | — |
| Q3 2021 | 2021-09-30 | $307,000 | $295,000 | +2458.33% |
| Q2 2021 | 2021-06-30 | $572,000 | — | — |
| Q1 2021 | 2021-03-31 | $2.5M | — | — |
| Q3 2020 | 2020-09-30 | $12,000 | — | — |
Pyxis Oncology stock-based compensation trends
Over the last five fiscal years, Pyxis Oncology's stock-based compensation increased from $44,000 to $11.8M, a change of $11.8M. The latest reported quarter, Q2 2026, shows $5.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pyxis Oncology source filings ↗